甘精胰岛素和格列齐特缓释片对初诊2型糖尿病患者的疗效比较

目的对糖化血红蛋白（HbAlc）在8％～10％的初诊为2型糖尿病的患者，在饮食、运动治疗的基础上，采用“甘精胰岛素加阿卡波糖”或“格列齐特缓释片加阿卡波糖”进行短期强化治疗，比较两种方案的疗效。方法将60例初诊的2型糖尿病患者随机分为两组，甘精胰岛素组采用甘精胰岛素联用阿卡波糖治疗，格列齐特组采用格列齐特缓释片联用阿卡波糖治疗，共12周，观察两组患者治疗前后血糖、糖化血红蛋白（HbAlc）、空腹胰岛素（Fins）、餐后胰岛素（2hIns）、胰岛素抵抗指数（HOMA—IR）及胰岛素分泌指数（HOMA—β）的变化。结果两种治疗方案均能显著降低血糖及HbAlc（P〈0．01），Fins升高（P〈0．05），HOMA—IR下降（P〈0．05），HOMA-β升高（P〈0．01），低血糖发生率低。甘精胰岛素组降低血糖的效果优于格列齐特组（P〈0．05）。结论两种强化方案对HbAlc在8％～10％的初诊2型糖尿病患者均有较好的疗效，且甘精胰岛素组降糖效果更加显著。

The comparison effect of short-term intensive therapy using glargine versus gliclazide in newly diagnosed type 2 diabetic patients

Objective To compare the effect of two different short-term intensive treatment （＂ Glargine and Acarbose＂ or ＂Gliclazide Sustained-release Tablets and Acarbose＂ ） , based on diet and exercise therapy,on the newly diagnosed type 2 diabetic patients by HbAlc in 8 to 10%. Methods 60 patients with type 2 diabetes were divided into two groups randomly. Glargine group were treated with glargine combined with acarbose, while gliclazide group were treated with Gliclazide Sustained-Release Tablets combineed with acarbose for 12 weeks. The change of blood glucose, glycated hemoglobin （ HbAlc）, fasting insulin （ Fins ）, postprandial insulin （ 2hIns ）, insulin resistance index （ HOMA-IR ） and insulin secretion index（HOMA-β） before and ＂after treatment were observed in two groups. Results The blood glucose, HbAlc, HOMA-IR and incidence of low blood sugar were significantly reduced, while the Fins and HOMA-β were markedly increased in both treated groups. The effect of reducing the blood sugar in glargine group is better than the gliclazide group （ P 〈 0.05 ）. Conclusions To newly diagnosed type 2 diabetes by HbAlc in 8 to 10% ,the treatment of two strengthen programs are both effective and the hypoglycemic effect of is more significant in glargine group.